A Phase Ib, Open-label, Dose Escalation with an Expansion Trial of a in Combination with B or a Plus Standard of Care in Patients With Xxx Cancer Eligible for Second Line Treatment

Study Identifier:
LCB-2301-002
CT.gov Identifier:
N/A
EudraCT Identifier:
202552000000
EU Trial (CTIS) Number:
2025-521582-27-00
Study Contact Information:
(210) 593-5651 or [email protected]
Recruitment Complete

Considering participating in a START clinical trial?

Get Started

Study Summary

To asses NILK-2301l combined Standard of Care in Patients With Cancer

Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Solid Tumor
Phase
The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
I
Sex
N/A
Age
18+ years
Study Drug
Drug: Patients will receive NILK-2301 combined with Standard of Care
Study Status
Indicates the current recruitment status or the expanded access status
Recruitment Complete

Requirements information
Inclusion criteria
  • Inclusion Criteria:
  • Patients with solid tumors

Clinical Study Information for Healthcare Providers

By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.

View Study Information

Study Locations

Location
Investigator
Status
Condition(s) Treated at Site
Location
START Madrid, Spain (FJD)
Madrid, Spain, 28040
Investigator
Victor Moreno Garcia
Status
Recruitment Complete
Condition(s) Treated at Site
Solid Tumor